Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Hawkey

Showing results (61-70 of 279) with videos related to

Pageof 28
Sort By:
Prostaglandins, Leukotrienes, and Medicine|September 1, 1983
A thromboxane synthetase inhibitor in Raynaud's phenomenonE W Jones, C J Hawkey
Expert Opinion on Investigational Drugs|July 5, 2005
Gastrointestinal effects of COX-2 inhibitorsL M Jackson, C J Hawkey
Clinical Nutrition (Edinburgh, Scotland)|February 1, 1992
Therapeutic approaches to the problem of biliary sludge and gallstone formation during total parenteral nutritionF E Murray, C J Hawkey
Gut|October 1, 1988
Medical treatment of ulcerative colitis: scoring the advancesC J Hawkey, A B Hawthorne
European Journal of Gastroenterology & Hepatology|February 12, 1998
Specific mediator-directed therapy for gastrointestinal diseasesW A Stack, C J Hawkey
The New England Journal of Medicine|January 31, 1998
Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's diseaseC J Hawkey, W A Stack
The American Journal of Medicine|May 8, 1998
Evolving strategies for managing nonsteroidal anti-inflammatory drug-associated ulcers: chairmen's introductionC J Hawkey, N D Yeomans
Best Practice & Research. Clinical Gastroenterology|February 28, 2002
Physiology and organ-related pathology of the elderly: stomach ulcersJ I Jones, C J Hawkey
Drugs|July 6, 2000
COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?L M Jackson, C J Hawkey
The American Journal of Medicine|February 13, 2001
Questions regarding future research on aspirin and the gastrointestinal tractB I Hirschowitz, C J Hawkey
Pageof 28

Showing results (61-70 of 279) with videos related to

Sort By:
Pageof 28
Prostaglandins, Leukotrienes, and Medicine|September 1, 1983
A thromboxane synthetase inhibitor in Raynaud's phenomenonE W Jones, C J Hawkey
Expert Opinion on Investigational Drugs|July 5, 2005
Gastrointestinal effects of COX-2 inhibitorsL M Jackson, C J Hawkey
Clinical Nutrition (Edinburgh, Scotland)|February 1, 1992
Therapeutic approaches to the problem of biliary sludge and gallstone formation during total parenteral nutritionF E Murray, C J Hawkey
Gut|October 1, 1988
Medical treatment of ulcerative colitis: scoring the advancesC J Hawkey, A B Hawthorne
European Journal of Gastroenterology & Hepatology|February 12, 1998
Specific mediator-directed therapy for gastrointestinal diseasesW A Stack, C J Hawkey
The New England Journal of Medicine|January 31, 1998
Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's diseaseC J Hawkey, W A Stack
The American Journal of Medicine|May 8, 1998
Evolving strategies for managing nonsteroidal anti-inflammatory drug-associated ulcers: chairmen's introductionC J Hawkey, N D Yeomans
Best Practice & Research. Clinical Gastroenterology|February 28, 2002
Physiology and organ-related pathology of the elderly: stomach ulcersJ I Jones, C J Hawkey
Drugs|July 6, 2000
COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?L M Jackson, C J Hawkey
The American Journal of Medicine|February 13, 2001
Questions regarding future research on aspirin and the gastrointestinal tractB I Hirschowitz, C J Hawkey
Pageof 28